NewsBenzinga하버드 바이오사이언스, 2026회계연도 매출 가이던스 8,828만 1천~9,001만 2천 달러에서 8,914만 7천~9,087만 7천 달러로 상향 조정, 예상치 8,979만 4천 달러 하버드 바이오사이언스, 2026회계연도 매출 가이던스 8,828만 1천~9,001만 2천 달러에서 8,914만 7천~9,087만 7천 달러로 상향 조정, 예상치 8,979만 4천 달러 Benzinga 2026.11.10 12:04 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients